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INTRODUCTION
Excessive bleeding in cardiac surgery increasesmorbidity and mortality.1,2 Children undergoing cardiacsurgery are at high risk of bleeding due to the use ofcardiopulmonary bypass circuit.3,4 Bleeding exposesthem to transfusion of blood products; hence, increasesrisk of transfusion complications.5 In cyanotic heartdisease, there is an even higher risk of bleeding due toinherent platelet dysfunction and fibrinolysis.6
Implementation of a good blood conservation plan canreduce bleeding and improve outcome.7 TXA is the mostcommon anti-fibrinolytic used in cardiac surgery.Systematic reviews suggest its use; and its safety is alsocompared with other anti-fibrinolytic drugs.8,9
Cyanotic congenital heart disease including TOF, singleventricle physiology, refers to a subset of congenitalheart disease (CHD) that often present soon after birth
with systemic hypoxemia; and hypoxia is related toimpaired pulmonary blood flow and mixing of pulmonaryand systemic venous blood.10 Only a few researchershave used TXA as haemostatic agent in cyanoticcongenital heart disease (CHD) surgeries in variousdoses and different regimens.
The aim of this study was to compare continuous infusionversus boluses of TXA in terms of reducing post-operative bleeding and chest closure time in cyanoticCHD surgeries.
METHODOLOGY
After ERC approval (4260-Ane-ERC-16) and consentfrom patients’ parents, this randomised single-blindedclinical trial was conducted at cardiac operating roomsand CICU of  The Aga Khan University Hospital, Karachi,from July 2016 to April 2017.
Inclusion criteria consisted of neonates to 16-year patienthaving first time on pump corrective or palliative cyanoticcongenital heart surgery. Exclusion criteria includedpatients with renal dysfunction (serum creatinine >1.5mg/dl), previous neurological event, congenital oracquired bleeding disorder (INR >1.5, history of easybruisebility) and allergy to tranexamic acid (1 ml=50 mgtest dose to test allergy given before full dose). The
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sample size was based on postoperative mean bloodloss for the first 24 hours of the patients in boluses group20 ±13 ml/kg.11 A 35% difference in the mean blood lossof (i.e.13 ±5) ml/kg between the Tranexamic infusion andboluses groups was suggested to be consideredsignificant. A sample size of 27 subjects in each groupwas considered sufficient to detect a 35% difference inblood loss with a power of 0.8 and type I error of 0.05. Itwas assumed that the study dropout rate would be 10%and, therefore, a total of 60 patients (30 in each group)were recruited.
After enrolment, selected patients were randomlyassigned into two groups using computer-generatedrandomisation (using software PASS, ver. 11.04 byrandomisation algorithm). Group I (Infusion) patients gotintravenous infusion of tranexamic acid at the rate of5 mg/kg/hour. It was started after induction andcontinued throughout surgery and postoperatively untilthe bleeding minimised (chest tube output 0.5-1ml/kg/hr.). Group B (Bolus group) got three intravenousboluses of tranexamic acid at induction, on commencementof CPB, and after protamine reversal. Each bolus was of10 mg/kg.
Surgical and bypass technique was tailored according tothe type of surgery. All patients were premedicated with0.5 mg/kg midazolam syrup. Standard ASA monitoringwas applied to all patients. Radial/femoral arterial linesand CVP (Right IJV or Femoral) lines were inserted in allpatients.
Primary outcome measures were sternal closure timeand postoperative bleeding. Chest closure was countedfrom completion of protamine administration tillapproximation of the sternum by tightening of sternalwires, and was documented in minutes. Postoperativebleeding was defined as bleeding occurring in ml/kgafter chest closure in the first 24 hours (at OR andCICU). Pleur-Evac graduated suction was used tomeasure blood loss. Chest closure time in minutes andamount of postoperative bleeding was measured inml/kg for 24 hours by primary investigator anddocumented in the pre-designed data collection form.Other variables, according to data collection form, werealso entered. Paediatric ICU team managed the patientspostoperatively.
All statistical analyses were performed using StatisticalPackages for Social Science version 19 (SPSS Inc.,Chicago, IL). Normality of age, weight, height, time tochest closure, and postoperative bleeding was checkedby Kolmogorov-Smirnov test, then student t-test andMann-Whitney test were used to compare mean/median[25th - 75th percentile] difference between groups.Frequency and percentage was computed for gender.A value of p <0.05 was considered as significant.
RESULTS
The mean age of the patients was 36.5 (13-63.75)months in group I (infusion) and 31 (17.5-75) months ingroup B (bolus). The mean body weight was 11 (8.7-14.1)Kg in group I and 12 (8.4-16.6) Kg in group B as shownin Table I. Patients underwent various types of surgeries,largely correction of Tetralogy of Fallot. The medianbypass time was 100 [80-126.25] minutes in group I and95 [75-131.75] minutes in group B. The median cross-clamp was 75 [58-92.5] minutes in group I and 65[53.75-90] minutes in group B.
Chest closure time in group I was 38.5 (25-45) minuteswhile in group B it was 30 (20-46.25) minutes.Postoperative bleeding in first 24 hours in group I was13.94 (10.27-20.18) ml/kg and in group B it was 15.05(9.04-23.50) ml/Kg. There was no significant statisticaldifference regarding postoperative bleeding at any timein the first 24 hours, and chest closure time between thetwo groups (Table II).
The frequency of blood products usage was alsoanalysed. Packed RBCs were required in 12 (40%)patients of group I; whereas, it was 13 (43.3%) in group Bpatients. Platelets were required in 15 (50%) patients ofgroup I and in 15 (50%) patients of group B. Freshfrozen plasmas (FFPs) were required in 4 (13.3%)patients of group I; whereas, 3 (10%) patients of group Bwere transfused with FFPs. Cryoprecipitate wererequired in 13 (43.3%) patients of group I; whereas, in 14(46.7%) patients of group B. Whole blood was used in 2(6.7%) and 6 (20%) patients in group I and group B,respectively (Table III).
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Table I: Demographic and surgical statistics of patients.
Variables Group I Group B P-value
(n=30) (n=30)
Age (Months)* 36.5[13-63.75] 31[17.5-75] 0.842
Height (cm)* 91[81.25-101] 90[77.13-109.75] 0.935
Weight (kg)* 11[8.7-14.1] 12[8.4-16.6] 0.912
BMI (kg/m2)* 13.9[12.5-15.2] 14.1[12.2-14.8] 0.941
Gender**
Male 16 (53.3%) 15 (50%) 0.796
Female 14 (46.7%) 15 (50%)
Procedure**
TOF repair 24 (80%) 22 (73.3%)
Glenn Shunt 3 (10%) 3 (10%)
Senning procedure 2 (6.6%) 0
Correction of TAPVR 0 2 (6.6%)
Correction of Cor-triatriatum 1 (3.3%) 0 0.934
Arterial switch 0 1 (3.3%)
Rastelli 0 1 (3.3%) 
VSD Closure + RV myomectomy 0 1 (3.3%)
Bypass time (Min) * 100[80-126.25] 95[75-131.75] 0.871
Cross Clamp Time (Min) * 75[58-92.5] 65[53.75-90] 0.291
Data are presented as *median [25th -75th Percentile], †mean ± SD and ‡n (%) Statistical Test: *Mann-Whitney U-test, **Chi-square test.
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DISCUSSION
This study found no statistical difference between tworegimens of TXA with respect to postoperative bleedingin the first 24 hours and chest closure time. Furthermore,any adverse major clinical outcome as renal, neurologicalor thromboembolic event were not found. In this study,there was a very much homogenous population ofpatients in terms of age, height, weight, distribution ofgender and type of surgery. All the surgeries were doneby one surgeon.
In another study, Couturier and colleagues sought toassess the effectiveness of continuous and discontinuousTXA by fibrinolytic parameters in on-pump paediatriccardiac surgery. They also concluded that continuousand discontinuous both inhibit fibrinolysis effectively.12
A study by Chauhan and colleagues used five differentregimens among which bolus group had decreasedblood loss among all groups, but maximum reductionwas in bolus group of 10 mg/kg after induction, on CPBand after Protamine. In this study, there was nostatistical difference in post-op bleeding in both groups.However, there is less bleeding and less use of bloodand blood products in comparison to study of Chauhanand colleagues.11
A study conducted by Faraoni and colleagues on theeffect of two doses of tranexamic acid on fibrinolysisevaluated by thromboelastography stated no differencebetween two different doses of TXA and placeboregarding fibrinolysis.13 In another study in adults, Sigautand colleagues observed high and low doses oftranexamic acid in terms of blood transfusion and found
no difference but higher dose was more effective interms of post-op bleeding and reopening.14
In a multicentre contemporary analysis of anti-fibrinolyticmedication in paediatric cardiac surgery, Pasquali andcolleagues found that TXA was associated withimproved outcomes in comparison to aprotinin, likedecrease in hospital mortality, bleeding requiringsurgical intervention, ICU length of stay and dialysis. Inredo-sternotomies, there were no differences detectedbetween TXA and aprotinin.15
In a RCT, Reid and colleagues found that TXA effectivelyreduces blood loss in children undergoing repeat cardiacsurgeries, although the dose used was high but still theyhaven't found any adverse event or complication of TXA.Total volume transfusion requirements and total unitexposure to banked blood components were also less inthe tranexamic acid group.16
Additionally, a study by Schindler and colleaguescollected data retrospectively and compared TXA as analternative to aprotinin in paediatric cardiac surgery andsuggested that TXA represent adequate alternation toaprotinin in congenital cardiac surgery.17
Chauhan and colleagues studied effectiveness of TXA incorrective surgeries of cyanotic CHD and proved that theTXA is highly effective in reducing postoperative bleedingand use of blood and blood products.18 Furthermore, aretrospective study of CHD patients undergoing cardiacsurgery, Giordano and colleagues showed that TXAsignificantly decreases postoperative bleeding andreduces intra-op and post-op RBCs transfusion.19
A study conducted by Martin and colleagues comparedTXA with e-ACA (epsilon-aminocaproic acid) and foundthat there was no difference between both drugs interms of blood loss, revision of surgery due to bleeding,and blood transfusion. They also found that there was nodifference in major clinical outcomes as renal,neurological, cardiovascular complications, and inhospital mortality.20 In a retrospective study Hasegawaand colleagues evaluated the effectiveness ofintraoperative TXA in blood-less cardiac surgery inchildren and found that intraoperative TXA was effectivefor both blood conservation and post-op clinicaloutcomes.21 In another study, Patel and colleaguesstudied to determine the effectiveness of Topical TXA in
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Table II: Comparison of postoperative bleeding (ml/kg) and chest closure time (minutes) between groups.
Variables Group I Group B P-value
n=30 n=30
n Median [25th-75th Percentile] N Median [25th-75th Percentile]
At 6 hours 30 7.40[4.32-11.42] 30 7.62[4.31-11.63] 0.97
6-12 hours 30 3.07[2.03-4.38] 30 2.20[1.08-3.78] 0.24
12-18 hours 30 2.19[1.48-2.51] 30 2.89[1.50-4.84] 0.13
18-24 hours 30 1.25[0.18-2.23] 30 1.15[0.0-2.37] 0.88
Total postoperative bleeding in 1st 24 hours 30 13.94[10.27-20.18] 30 15.05[9.04-23.50] 0.679
Chest closure time 30 38.5[25-45] 30 30[20-46.25] 0.152
Data are presented as median [25th -75th Percentile]. Statistical test:  Mann-Whitney U-test.
Table III: Blood products and its component used.
Use of blood products Group I Group B P-value
(n=30) (n=30)
Priming of CPB circuit with blood product:
PRBCs 18 (60%) 15 (50%) 0.436
FFPs 8 (26.7%) 4 (13.3%) 0.197
Blood product usage (In OR and CICU first 24 hrs.):
PRBCs 12 (40%) 13 (43.3%) 0.793
Platelets 15 (50%) 15 (50%) 0.999
FFPs 4 (13.3%) 3 (10%) 0.688
Cryoprecipitate 13 (43.3%) 14 (46.7%) 0.795
Whole Blood 2 (6.7%) 6 (20%) 0.254
Data are presented n (%), mean ± SD (min-max);   Statistical Test:  Chi-square test. 
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paediatric cardiac surgery. They concluded that thecombination of low dose systemic TXA and topical TXAintrapericadially before chest closure was the best.22 Ina clinical review, William and colleagues observed thatpractice of TXA as antifibrinolytic in intra-op and peri-opsettings has strong pharmacological and clinicalgrounds. They found that TXA can be used effectively inadult cardiac surgery, paediatric cardiac and non-cardiacsurgery, orthopaedic surgery, neurosurgery, hepaticsurgery, and gynaecology and obstetrics surgeries.23
The limitation of this study was attributed to its smallsample size, majority of the cases were correction ofTOF, and it was also a single-blinded study. Therefore infuture, a large sample size study needs to be conductedto validate these results. The lack of statisticallysignificant difference among the groups may beevaluated in a further high sample size and adequatelypowered study with more standardised anaesthetic,surgical, and bypass techniques.
CONCLUSION
There was no statistical and clinical difference betweeninfusion and bolus group with respect to postoperativebleeding and chest closure time. However, post-operative bleeding was little less in volume in infusiongroup, but paradoxically chest closure time was little lessin bolus group.
REFERENCES
1. Ranucci M, Baryshnikova E, Castelvecchio S, Pelissero G,Surgical, Group COR. Major bleeding, transfusions, andanemia: the deadly triad of cardiac surgery. Ann Thorac Surg2013; 96:478-85.
2. Petäjä J, Lundström U, Leijala M, Peltola K, Siimes MA.Bleeding and use of blood products after heart operations ininfants. J Thorac Cardiovasc Surg 1995; 109:524-9.
3. Bronicki RA, Hall M. Cardiopulmonary bypass-inducedinflammatory response: pathophysiology and treatment.Pediatr Crit Care Med 2016; 17(8_suppl):S272-S8.
4. Kraft F, Schmidt C, Van Aken H, Zarbock A. Inflammatoryresponse and extracorporeal circulation. Best Pract Res ClinAnaesthesio 2015; 29:113-23.
5. Spiess BD. Blood transfusion and infection after cardiacsurgery. Ann Thorac Surg 2013; 95:1855-8.
6. Tempe DK, Virmani S. Coagulation abnormalities in patientswith cyanotic congenital heart disease. J Cardiothorac VascAnesth 2002; 16:752-65.
7. LaPar DJ, Crosby IK, Ailawadi G, Ad N, Choi E, Spiess BD, et al.Blood product conservation is associated with improvedoutcomes and reduced costs after cardiac surgery. J ThoracCardiovasc Surg 2013; 145:796-804.
8. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect oftranexamic acid on surgical bleeding: systematic review andcumulative meta-analysis. BMJ 2012; 344:e3054.
9. Lin CY, Shuhaiber JH, Loyola H, Liu H, del Nido P, DiNardo JA,et al. The safety and efficacy of antifibrinolytic therapy inneonatal cardiac surgery. PloS One 2015; 10:e0126514.
10. Opotowsky AR, Moko LE, Ginns J, Rosenbaum M, Greutmann M,Aboulhosn J, et al. Pheochromocytoma and paraganglioma incyanotic congenital heart disease. J Clin Endocrinol Metab2015; 100:1325-34.
11. Chauhan S, Bisoi A, Kumar N, Mittal D, Kale S, Kiran U, et al.Dose comparison of tranexamic acid in pediatric cardiacsurgery. Asian Cardiovasc Thorac Ann 2004; 12:121-4.
12. Couturier R, Rubatti M, Credico C, Louvain-Quintard V,Anerkian V, Doubine S, et al. Continuous or discontinuoustranexamic acid effectively inhibits fibrinolysis in childrenundergoing cardiac surgery with cardiopulmonary bypass.Blood Coagul Fibrinolysis 2014; 25:259-65.
13. Faraoni D, Cacheux C, Van Aelbrouck C, Ickx BE, Barvais L,Levy JH. Effect of two doses of tranexamic acid on fibrinolysisevaluated by thromboelastography during cardiac surgery: arandomised, controlled study. Eur J Anaesthesiol 2014; 31:491-8.
14. Sigaut S, Tremey B, Ouattara A, Couturier R, Taberlet C,Grassin-Delyle S, et al. Comparison of two doses oftranexamic acid in adults undergoing cardiac surgery withcardiopulmonary bypass. J Am Soc Anesthesiol. 2014; 120:590-600.
15. Pasquali SK, Li JS, He X, Jacobs ML, O'Brien SM, Hall M,et al. Comparative analysis of antifibrinolytic medications inpediatric heart surgery. J Thorac Cardiovasc Surg 2012; 143:550-7.
16. Reid RW, Zimmerman AA, Laussen PC, Mayer JE, Gorlin JB,Burrows FA. The efficacy of tranexamic acid versus placebo indecreasing blood loss in pediatric patients undergoing repeatcardiac surgery. Anesth Analg 1997; 84:990-6.
17. Schindler E, Photiadis J, Sinzobahamvya N, Döres A, Asfour B,Hraska V. Tranexamic acid: an alternative to aprotinin asantifibrinolytic therapy in pediatric congenital heart surgery.Eur J Cardiothorac Surg 2011; 39:495-9.
18. Chauhan S, Bisoi A, Modi R, Gharde P, Rajesh M. Tranexamicacid in paediatric cardiac surgery. Indian J Med Res 2003;118:86.
19. Giordano R, Palma G, Poli V, Palumbo S, Russolillo V, Cioffi S,et al. Tranexamic acid therapy in pediatric cardiac surgery: asingle-center study. Ann Thorac Surg 2012; 94:1302-6.
20. Martin K, Breuer T, Gertler R, Hapfelmeier A, Schreiber C,Lange R, et al. Tranexamic acid versus -aminocaproic acid:efficacy and safety in paediatric cardiac surgery. Eur JCardiothorac Surg 2011; 39:892-7.
21. Hasegawa T, Oshima Y, Maruo A, Matsuhisa H, Tanaka A,Noda R, et al. Intraoperative tranexamic acid in pediatricbloodless cardiac surgery. Asian Cardiovasc Thorac Ann 2014;22:1039-45.
22. Patel J, Prajapati M, Patel H, Gandhi H, Deodhar S, Pandya H.Topical and low-dose intravenous tranexamic acid in cyanoticcardiac surgery. Asian Cardiovasc Thorac Ann 2017; 25:118-22.
23. Ng WCK, Jerath A, Wasowicz M. Tranexamic acid: a clinicalreview. Anaesthesiol Intensive Ther 2015; 47:339-50.
